FEB 22, 2016 2:42 PM PST

New T-Cell Leukemia Treatment Target Identified

WRITTEN BY: Kara Marker
Around 15 to 20 percent of children with acute lymphoblastic leukemia (ALL) have cancerous cells derived from T lymphocytes (immune cells), as opposed to B lymphocytes (American Cancer Society). Currently, over half of adults and 20 percent of children with T-cell ALL end up dying. New research from Boston University Medical College (BUMC) researchers offers a potential solution for lowering those fatality rates; their new study published in Leukemia  identifies a specific enzyme that cancer cells rely on for survival.
 

 
During the tricarboxylic acid (TCA) cycle, a key step in the process of cellular aerobic respiration, cells transform pyruvate received from glycolysis into energy through oxidation of acetyl-CoA (Georgia State University). The new BUMC study identified a key enzyme involved in this process called DLST, which cancer cells require for adequate growth and survival. They discovered the cancer cell dependence on DLST by performing genetic screenings on a zebrafish model of disease, looking for specific mutations that suppress tumor development.
 
Indeed, inhibiting DLST in the zebra fish model “significantly delayed tumor onset in zebrafish without detectable effects on fish development” (Leukemia 2016). They also successfully tested DLST enzyme activity inhibition with human T-cell leukemia cells.
 
A new prospect for T-cell ALL treatment utilizing DLST inhibition is promising, especially because current treatments for this cancer are highly toxic even if they are successful in healing the patient. This finding is also significant because prior to this research, scientists did not believe that cancer cells relied on the TCA cycle for survival.
 
“Our new findings provide solid evidence that these cancer cells depend on the TCA cycle for their survival," explained corresponding author Hui Feng, MD, PhD. "Additionally we demonstrated the importance of DLST in T-cell leukemia development, and have identified a targetable enzyme for T-cell leukemia treatment.”
 

Source: BUMC
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
SEP 11, 2020
Immunology
Study Reveals Tumor Defense Mechanism... And How to Beat It
SEP 11, 2020
Study Reveals Tumor Defense Mechanism... And How to Beat It
  P53 is an infamous process gene at the core of the development of tumors.  When P53  functional, it pau ...
OCT 24, 2020
Immunology
New CRISPR-Based Imaging Tool Is Going to Be HiUGE
OCT 24, 2020
New CRISPR-Based Imaging Tool Is Going to Be HiUGE
A team of researchers at Duke University have developed an imaging technology for tagging structures at a cellular level ...
NOV 02, 2020
Immunology
New Cancer Drug Reboots Stalled Immunotherapies
NOV 02, 2020
New Cancer Drug Reboots Stalled Immunotherapies
In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumo ...
NOV 09, 2020
Drug Discovery & Development
New Immunotherapy Shows Promise for MS
NOV 09, 2020
New Immunotherapy Shows Promise for MS
Researchers from Thomas Jefferson University in Philadelphia are studying an immunotherapy that has shown early pro ...
NOV 09, 2020
Drug Discovery & Development
COVID-19 Vaccine by Pfizer More than 90% Effective
NOV 09, 2020
COVID-19 Vaccine by Pfizer More than 90% Effective
A preliminary analysis of Pfizer and BioNTech's COVID-19 vaccine shows that it can prevent over 90% of people from c ...
NOV 25, 2020
Immunology
Another COVID-19 vaccine shows promising results!
NOV 25, 2020
Another COVID-19 vaccine shows promising results!
A week ago, another biotechnology company "Moderna" announced the preliminary results from its COVID-19 vaccin ...
Loading Comments...